Svenja Adrian

464 total citations
14 papers, 270 citations indexed

About

Svenja Adrian is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Svenja Adrian has authored 14 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Svenja Adrian's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Svenja Adrian is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Svenja Adrian collaborates with scholars based in Germany, Spain and United States. Svenja Adrian's co-authors include Éva Kevei, Wojciech Pokrzywa, Jörg Höhfeld, Thorsten Hoppe, Niki Karachaliou, Felix Hoppe‐Seyler, Xiuning Le, Karin Hoppe‐Seyler, Julien Mazières and Yi‐Long Wu and has published in prestigious journals such as Cell, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Svenja Adrian

14 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Svenja Adrian Germany	7	128	116	103	40	39	14	270
Gloria Yiu United States	8	169 1.3×	60 0.5×	161 1.6×	68 1.7×	48 1.2×	18	358
Yuyan Xu China	11	187 1.5×	35 0.3×	75 0.7×	23 0.6×	74 1.9×	39	333
Xu Shi China	12	146 1.1×	165 1.4×	58 0.6×	10 0.3×	153 3.9×	24	316
María Pérez-Lanzón France	8	106 0.8×	30 0.3×	91 0.9×	29 0.7×	26 0.7×	14	211
Landon Wark Canada	10	206 1.6×	33 0.3×	79 0.8×	18 0.5×	46 1.2×	15	313
Zan Lv China	10	169 1.3×	57 0.5×	65 0.6×	26 0.7×	50 1.3×	11	350
Amy E. Schade United States	7	249 1.9×	31 0.3×	117 1.1×	13 0.3×	44 1.1×	10	337
Vincent Yeung United States	5	206 1.6×	22 0.2×	98 1.0×	16 0.4×	41 1.1×	14	275
Sarah Koushyar United Kingdom	8	254 2.0×	96 0.8×	64 0.6×	16 0.4×	87 2.2×	12	347
Terry J. Shackleford United States	6	220 1.7×	48 0.4×	114 1.1×	21 0.5×	64 1.6×	11	320

Countries citing papers authored by Svenja Adrian

Since Specialization

Citations

This map shows the geographic impact of Svenja Adrian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svenja Adrian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svenja Adrian more than expected).

Fields of papers citing papers by Svenja Adrian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svenja Adrian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svenja Adrian. The network helps show where Svenja Adrian may publish in the future.

Co-authorship network of co-authors of Svenja Adrian

This figure shows the co-authorship network connecting the top 25 collaborators of Svenja Adrian. A scholar is included among the top collaborators of Svenja Adrian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svenja Adrian. Svenja Adrian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Morise, Masahiro, Terufumi Kato, Shingo Matsumoto, et al.. (2024). Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer Science. 115(4). 1296–1305. 3 indexed citations

Nadal, Ernest, Valentina Guarneri, Marie Wislez, et al.. (2023). 1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC. Annals of Oncology. 34. S780–S781. 1 indexed citations

Paik, Paul K., Marina Chiara Garassino, Xiuning Le, et al.. (2023). Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.. Journal of Clinical Oncology. 41(16_suppl). 9060–9060. 2 indexed citations

Tan, Daniel Shao-Weng, Tae Min Kim, Valentina Guarneri, et al.. (2023). Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.. Journal of Clinical Oncology. 41(16_suppl). 9021–9021. 16 indexed citations

Mazières, Julien, Marie Wislez, Christophe Dooms, et al.. (2022). LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. Annals of Oncology. 33. S1419–S1420. 27 indexed citations

Le, Xiuning, Luis Paz‐Ares, Jan P. van Meerbeeck, et al.. (2022). Tepotinib in Patients with Advanced NSCLC with MET Amplification (METamp). International Journal of Radiation Oncology*Biology*Physics. 112(2). e6–e7. 1 indexed citations

Reinmuth, Niels, Sanjay Popat, Luis Paz‐Ares, et al.. (2021). 1255P Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S985–S986. 2 indexed citations

Le, Xiuning, Luis Paz‐Ares, Jan P. van Meerbeeck, et al.. (2021). Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).. Journal of Clinical Oncology. 39(15_suppl). 9021–9021. 30 indexed citations

Tabernero, Josep, Eric Van Cutsem, Jana Prausová, et al.. (2021). Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).. Journal of Clinical Oncology. 39(3_suppl). TPS149–TPS149. 3 indexed citations

10.

Smit, Egbert F., Christophe Dooms, Jo Raskin, et al.. (2021). INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance. Future Oncology. 18(9). 1039–1054. 35 indexed citations

11.

Bossler, Felicitas, Thomas Günther, Svenja Adrian, et al.. (2019). Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. mBio. 10(1). 41 indexed citations

12.

Pokrzywa, Wojciech, et al.. (2017). The Ubiquitin Ligase CHIP Integrates Proteostasis and Aging by Regulation of Insulin Receptor Turnover. Cell. 169(3). 470–482.e13. 95 indexed citations

13.

Hoppe‐Seyler, Karin, et al.. (2017). Virus/Host Cell Crosstalk in Hypoxic HPV-Positive Cancer Cells. Viruses. 9(7). 174–174. 13 indexed citations

14.

Adrian, Svenja, et al.. (2010). Clinical experience with carboplatin (CBDCA) and oral vinorelbine (NVBO) in first-line advanced non-small cell lung cancer (NSCLC) treatment.. Journal of Clinical Oncology. 28(15_suppl). e18143–e18143. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact